Search results for "OUTCOME"

showing 10 items of 5148 documents

Glucose insulin potassium infusion improves systolic function in patients with chronic ischemic cardiomyopathy

2002

Objective: We assessed the effects of glucose–insulin–potassium (GIK) by echocardiography in stable patients with ischemic dysfunction. Methods: Twelve male patients with stable coronary disease (SCD) and ejection fraction (EF) <45% were studied for systolic function. GIK (glucose 30%, 300 insulin units and KCl 6 g/l) was infused at 1 ml/kg per h over 20 min. Hemodynamic and echocardiographic measurements were recorded at rest (T0), at the end (20 min) of GIK infusion (T + 20), 20 and 40 min after the end of the infusion (T + 40 and T + 60). Results: At T + 20, a significant decrease in WMSI (wall motion score index) was observed compared with T0 (2.16±0.14 vs. 2.30±0.16: P<0.05). An increa…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentHemodynamicsBlood PressureSystolic functionVentricular Dysfunction LeftHeart RateInternal medicinemedicineHumansInsulinIn patientInfusion PumpsAgedEjection fractionIschemic cardiomyopathyGlucose insulin potassiumbusiness.industryInsulinStroke VolumeMiddle Agedmedicine.diseaseGlucoseTreatment OutcomeEchocardiographyHeart failureChronic DiseasePotassiumCardiologyCardiomyopathiesCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesEuropean Journal of Heart Failure
researchProduct

Hepatitis C virus viral kinetics during α-2a or α-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immuno…

2012

Abstract Background Predictors of sustained virological response (SVR) to antiviral therapy post-liver transplantation (LT) for chronic hepatitis C are needed. In non-transplanted patients, viral kinetics can predict SVR. Objectives To determine the early viral kinetics in LT recipients with different immunosuppression (tacrolimus – Tac- vs. cyclosporine – CsA-) during treatment with peg-IFN + RBV. Study design Prospective pilot study in HCV-1b infected patients: (LT CsA n = 8; Tac n = 8; non-LT n = 4), treated with IFN α-2a vs. α-2b (180 μg or 1.5 μg/kg, respectively) once weekly plus weight-based RBV. Median CsA or Tac baseline trough levels were 141 and 7.70 ng/mL, respectively. HCV-RNA …

AdultMalemedicine.medical_specialtymedicine.medical_treatmentHepatitis C virusPilot ProjectsHepacivirusInterferon alpha-2Biologymedicine.disease_causeAntiviral AgentsGastroenterologyPolyethylene GlycolsImmunocompromised Hostchemistry.chemical_compoundPegylated interferonVirologyInternal medicineRibavirinmedicineHumansProspective StudiesAgedRibavirinInterferon-alphaImmunosuppressionHepatitis C ChronicMiddle AgedViral LoadViral kineticsRecombinant ProteinsTacrolimusLiver TransplantationTransplantationKineticsTreatment OutcomeInfectious DiseaseschemistryHost-Pathogen InteractionsImmunologyFemaleViral loadmedicine.drugJournal of Clinical Virology
researchProduct

Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease

2013

Background Nasal polyposis frequently occurs within the clinical picture of aspirin-exacerbated respiratory disease (AERD). A derailed arachidonic acid metabolism is regarded to be part of the pathophysiology of AERD, and aspirin desensitization is the only causal therapeutic option, so far. The optimal maintenance dose of aspirin desensitization to prevent nasal polyp recurrence on the one hand and to minimize aspirin-related side-effects, on the other hand, is still a matter of debate. The aim of this trial was to investigate the efficacy and safety of a low-dose aspirin desensitization protocol. Methods After sinus surgery, 70 individuals with AERD were randomly allocated to a prospectiv…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentImmunologylaw.inventionDrug HypersensitivityQuality of lifeRandomized controlled trialRecurrencelawSurveys and QuestionnairesInternal medicineRespiratory HypersensitivitymedicineHumansImmunology and AllergyDesensitization (medicine)AspirinAspirinMaintenance dosebusiness.industryRespiratory diseaseMiddle Agedmedicine.diseasePathophysiologyClinical trialTreatment OutcomeDesensitization ImmunologicAnesthesiaQuality of LifeFemalebusinessFollow-Up Studiesmedicine.drugAllergy
researchProduct

Endovascular treatment as first choice in chronic intestinal ischemia.

2002

The purpose of this study was to define the place of endovascular treatment in chronic intestinal ischemia (CII). We report here a series of 19 consecutive patients treated with percutaneous angioplasty of the intestinal arteries. We excluded patients with acute ischemia, from the study. From January 1, 1989 to December 31, 2001, 19 patients with symptomatic CII were treated by endovascular techniques. This study group included 11 men and 8 women with a mean age of 59 years (range 30 to 90 years). The clinical presentation included postprandial pain in 16 patients, weight loss in 14 patients, with a mean weight loss of 7.4 kg (range 0 to 30 kg); and gastroparesis in 2 patients. Stenoses wer…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentInferior mesenteric arteryBlood Vessel Prosthesis ImplantationIntestinal arteriesPostoperative ComplicationsCeliac arteryIschemiaAngioplastymedicine.arteryInternal medicineMedicineHumansSuperior mesenteric arteryThrombusAgedUltrasonographyAged 80 and overbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseSurgeryIntestinesStenosismedicine.anatomical_structureTreatment OutcomeChronic DiseaseCardiologySurgeryFemaleStentsCardiology and Cardiovascular MedicinebusinessVascular Surgical ProceduresArteryFollow-Up StudiesAnnals of vascular surgery
researchProduct

Successful pregnancy and childbirth after intracytoplasmic sperm injection with calcium ionophore oocyte activation in a globozoospermic patient

2007

Objective To check the effectiveness of intracytoplasmic sperm injection (ICSI) combined with assisted oocyte activation (AOA) in a globozoospermic patient. Design Case report. Setting Instituto Valenciano de Infertilidad, Valencia, Spain. Patient(s) A patient with globozoospermia. Intervention(s) ICSI was administered in 14 oocytes. ICSI combined with AOA, in which a small amount of calcium was injected followed by calcium ionophore exposure, was done in 9 oocytes. Main Outcome Measure(s) Fertilization rate and embryo quality was assessed in both groups. Result(s) Chemical activation increased fertilization rate (55.6% vs. 35.7%) and the number of embryos with less multinucleation on day 2…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentIntracytoplasmic sperm injectionAndrologyHuman fertilizationPregnancyHumansMedicineSperm Injections IntracytoplasmicGlobozoospermiaAzoospermiaGynecologyAzoospermiaPregnancyIonophoresbusiness.industryFertility Agents MaleObstetrics and GynecologyOocyte activationEmbryomedicine.diseaseCombined Modality TherapyTreatment OutcomeReproductive Medicineembryonic structuresOocytesCalciumFemalebusinessLive BirthEmbryo qualityFertility and Sterility
researchProduct

5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: A multicenter randomised phase II study of the Souther…

2000

The combination regimen CPT-11 plus bolus and infusion 5-fluorouracil (5-FU) with high-dose leucovorin (hybrid regimen LV5FU2) has been tested for activity and toxicity against advanced colorectal carcinoma in a randomised, multicenter phase II trial.A total of 102 chemotherapy-naïve patients were randomised in a 1:2 fashion to receive: leucovorin 100 mg/m2 administered as a two-hour infusion before 5-FU 400 mg/m2 as an intravenous bolus, and FU 600 mg/m2 as a 22-hour infusion immediately after 5-FU bolus injection repeated on days 1 and 2 (LV5FU2 regimen, arm A, 34 patients) or CPT-11 at 180 mg/m2 (150 mg/m2 for patients of ageor = 70 and75 years) only on day 1 immediately before LV5FU2 th…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentLeucovorinPhases of clinical researchIrinotecanGastroenterologyDisease-Free SurvivalFolinic acidBolus (medicine)Internal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions IntravenousAgedChemotherapybusiness.industryHematologyMiddle AgedChemotherapy regimenSurgeryIrinotecanRegimenTreatment OutcomeOncologyFluorouracilInjections IntravenousCamptothecinFemaleFluorouracilColorectal Neoplasmsbusinessmedicine.drugAnnals of Oncology
researchProduct

TIPS for acute and chronic Budd-Chiari syndrome: a single-centre experience.

2003

Abstract Background/Aims : Transjugular intrahepatic portosystemic shunt (TIPS) is a technically challenging but feasible treatment for Budd–Chiari syndrome (BCS). However, information about the outcome, particularly in patients with liver failure, is scarce. We report our experience of TIPS for BCS. Methods : Fifteen patients with BCS underwent TIPS. Eight had hepatic failure and seven underwent TIPS for BCS uncontrolled by medical treatment. Results : Fourteen out of 15 had successful TIPS placement. Out of the eight hepatic failure patients, four died soon after TIPS: one liver rupture, one portal vein rupture, one liver failure and one pulmonary oedema. Another patient had a significant…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentLiver transplantationBudd-Chiari SyndromeBalloonCatheterizationAscitesmedicineHumansAgedHepatologybusiness.industryVascular diseaseLiver failureMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeChronic DiseaseRetreatmentBudd–Chiari syndromeFemaleStentsLiver functionmedicine.symptomPortasystemic Shunt Transjugular IntrahepaticbusinessTransjugular intrahepatic portosystemic shuntLiver FailureJournal of hepatology
researchProduct

Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder.

2011

Abstract Background To examine the influencing factors and predictors of early improvement in schizophrenia patients. Methods 370 patients suffering from a schizophrenia spectrum disorder were examined within a naturalistic multicenter study. Early improvement was defined as a ≥30% PANSS total score reduction within the first two treatment weeks, response as a ≥50% improvement of the PANSS total score from admission to discharge and remission according to the consensus remission criteria. Baseline and course-related variables such as positive, negative and depressive symptoms, side effects, functioning and subjective well-being were examined regarding their explanatory value for early impro…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentMedizinAntipsychotic treatment03 medical and health sciencesYoung Adult0302 clinical medicineRemission criteriaPredictive Value of TestsInternal medicinemedicineHumansPsychiatryAntipsychoticBiological PsychiatryDepressive symptomsRetrospective StudiesPsychiatric Status Rating Scalesbusiness.industryMiddle Agedmedicine.disease030227 psychiatry3. Good healthDiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthTreatment OutcomeMulticenter studyROC CurveSchizophreniaSchizophreniaFemalebusiness030217 neurology & neurosurgerySchizophrenia spectrumAntipsychotic AgentsFollow-Up StudiesJournal of psychiatric research
researchProduct

Subtotal esophageal resection in motility disorders of the esophagus.

2005

&lt;i&gt;Background:&lt;/i&gt; Esophagectomy for motility disorders is performed infrequently. It is indicated after failed medical therapy, pneumatic dilation, non-resecting surgical and redo procedures. Patient selection in this group is challenging and the operative risk has to be weighted carefully against the poor quality of life with persistent or recurrent dysphagia. &lt;i&gt;Patients and Methods:&lt;/i&gt; Between September 1985 and April 2004, subtotal esophageal resections for advanced esophageal motility disorders of the esophagus not responding to previous therapy were carried out in 8 patients (6 females, 2 males). The median age of these patients was 59.5 (43–78) years. Six pa…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentMotilityResectionMedicineHumansEsophageal Motility DisordersEsophagusIntestinal MucosaAgedRetrospective StudiesPneumatic dilationHyperplasiabusiness.industryGeneral surgeryGastroenterologyMuscle SmoothGeneral MedicineLong term resultsMiddle AgedSurgeryEsophagectomyRadiographymedicine.anatomical_structureTreatment OutcomeEsophagectomyFemalebusinessMedical therapyFollow-Up StudiesDigestive diseases (Basel, Switzerland)
researchProduct

Etoposide Treatment in Recurrent Medulloblastoma

1994

Five consecutive patients with recurrent medulloblastoma received etoposide 120 mg/m2 for 5 to 7 days at 2 to 4-week intervals. Three patients with neuroaxis dissemination received additional intrathecal chemotherapy with methotrexate, cytosine arabinoside and prednisone. Toxicity consisted of alopecia and mild neutropenia. Complete response was registered in two patients, partial response in one. Median survival was 19 months with the 3 responders living 6, 30 and 60+ months. Etoposide seems to be an active agent in medulloblastoma.

AdultMalemedicine.medical_specialtymedicine.medical_treatmentNeutropeniaGastroenterologyRecurrencePrednisoneInternal medicinemedicineHumansSpinal Cord NeoplasmsNeoplasm MetastasisChildEtoposideEtoposideMedulloblastomaChemotherapyBrain Neoplasmsbusiness.industryGeneral MedicineRecurrent MedulloblastomaPrognosismedicine.diseaseFrontal LobeSurgeryTreatment OutcomeChild PreschoolPediatrics Perinatology and Child HealthToxicityFemaleMethotrexateNeurology (clinical)Tomography X-Ray ComputedbusinessMedulloblastomamedicine.drugNeuropediatrics
researchProduct